Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 14Terminated 3Recruiting 2Withdrawn 1Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Small Cell Lung Carcinoma 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1

Interventions

pembrolizumab 567Specimen Handling 487Carboplatin 456Magnetic Resonance Spectroscopy 442Cyclophosphamide 418Cisplatin 412Radiotherapy 353Gemcitabine 318Bevacizumab 317Paclitaxel 304Biopsy 291Drug Therapy 286Blood Specimen Collection 249Capecitabine 244Oxaliplatin 242fludarabine 238Nivolumab 236venetoclax 227Injections 214Docetaxel 209Fluorouracil 204Dexamethasone 187Radiosurgery 182Rituximab 162Pemetrexed 160Standard of Care 156Surgical Procedures, Operative 148durvalumab 146atezolizumab 146tislelizumab 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × amrubicin × Clear all
NCT06801834 2026-05-20

EVOKE-SCLC-04

Gilead Sciences

Phase 3 Recruiting
695 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT06203210 2026-03-02

IDeate-Lung02

Daiichi Sankyo

Phase 3 Recruiting
540 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡